Results With Viabahn-Assisted Subintimal Recanalization for TASC C and TASC D Superficial Femoral Artery Occlusive Disease

Abstract

Objectives: Many investigators including TransAtlantic Inter-Society Consensus (TASC) recommend against primary endovascular treatment for severe (TASC C and D) superficial femoral artery (SFA) disease. Vein bypass is preferable but may not be appropriate due to comorbidities or lack of suitable vein. This study reviews our results with Viabahn stent graft-assisted subintimal recanalization (VASIR) for TASC C and D SFA atherosclerosis. Methods: In all, 13 males and 14 females, mean age 72 ± 11 years underwent 28 VASIR for severe (TASC C 8 of 28, TASC D 20 of 28, and 5 of 28 no continuous infrapopliteal runoff artery) SFA disease. Indications were claudication (14 of 28 limbs), ischemic rest pain (6 of 28), and tissue loss (8 of 28). Viabahn stent graft-assisted subintimal recanalization was chosen instead of bypass due to comorbidities or lack of vein. Patients received aspirin and, if not already taking warfarin, they also received clopidogrel. Patients were examined with Ankle-brachial Index (ABI) and duplex scan at 1 month, then every 3 months after VASIR. Results Viabahn stent graft-assisted subintimal recanalization was technically successful in all. Ankle-brachial Index averaged 0.47 ± 0.17 preprocedure, 0.89 ± 0.20 postprocedure, and increased by 0.15 or more in every case. Median follow-up is 20 months. There were 3 perioperative (<30 days) and 7 later failures including revision prior to any thrombosis. One patient required amputation. Four have died, 2 with patent grafts, none from causes related to VASIR, all more than 30 days post-VASIR. Estimated 1-year primary and secondary patency were 70% ± 11% and 73% ± 10%. Failure was not significantly associated with indications, comorbidities, or runoff status. There was a clear distinction between patients with early failure and the rest of the patients. None of the 8 patients with failure in the first 8 months after surgery has a patent graft. However, of 17 grafts primarily patent at 8 months, only 2 have failed (1 thrombosed and 1 required preemptive balloon angioplasty). There was a strong trend toward better patency with 6 and 7 mm diameter compared to 5 mm diameter stent grafts. Furthermore, although warfarin was not prescribed as part of the protocol, no patient taking warfarin before and who resumed warfarin after VASIR (n = 4) suffered failure. Conclusions: Despite significant early failures, we found VASIR to be durable in those who did not have early failure. Viabahn stent graft-assisted subintimal recanalization is an acceptable alternative to vein bypass in selected patients with severe SFA disease. Smaller arterial or stent graft diameter may be associated with poorer results. Warfarin may be valuable to reduce the risk of failure after VASIR.

Keywords

TASC endovascular therapy stent graft

Get full access to this article

View all access options for this article.

References

Dormandy JA , Rutherford RB Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1-S296.

Bolia A. , Miles KA , Brennan J. , Bell PR Percutaneous transluminal angioplasty of occlusions of the femoral and popliteal arteries by subintimal dissection. Cardiovasc Intervent Radiol . 1990;13(1): 357-363.

Zdanowski Z. , Albrechtsson U. , Lundin A. , et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol. 1999;18(4):251-255.

Lampmann LE Stenting in the femoral superficial artery: an overview. Eur J Radiol. 1999;29(3):276-279.

Yilmaz S. , Sindel T. , Yegin A. , Luleci E. Subintimal angioplasty of long superficial femoral artery occlusions. J Vasc Interv Radiol. 2003;14(8):997-1010.

Becquemin J-P. , Favre J-P. , Marzelle J. , Nemoz C. , Corsin C. , Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multi-center prospective randomized study. J Vasc Surg. 2003;37(3): 487-494.

Hynes N. , Akhtar Y. , Manning B. , et al. Subintimal angioplasty as a primary modality in the management of critical limb ischemia: comparison to bypass grafting for aortoiliac and femoropopliteal occlusive disease. J Endovasc Ther Official J Int Soc Endovasc Special. 2004;11(4):460-471.

Saketkhoo RR , Razavi MK , Padidar A. , Kee ST , Sze DY , Dake MD Percutaneous bypass: subintimal recanalization of peripheral occlusive disease with IVUS guided luminal re-entry. Tech Vasc Intervent Radiol. 2004;7(1):23-27.

Lipsitz EC , Veith FJ , Ohki T. Subintimal angioplasty in the management of critical lower-extremity ischemia: value in limb salvage. Perspect Vasc Surg Endovasc Ther. 2005;17(1):11-20.

10.

Abahji TN , Tato F. , Rieger J. , et al. Stenting of the superficial femoral artery after suboptimal balloon angioplasty: one-year results. Int Angiol. 2006;25(2):184-189.

11.

Myers SI , Myers DJ , Ahmend A. , Ramakrishnan V. Preliminary results of subintimal angioplasty for limb salvage in lower extremities with severe chronic ischemia and limb-threatening ischemia. J Vasc Surg. 2006;44(6):1239-1246.

12.

Treiman GS , Treiman R. , Whiting J. Results of percutaneous subintimal angioplasty using routine stenting. J Vasc Surg. 2006;43(3):513-519.

13.

Scott EC , Biuckians A. , Light RE , Burgess J. , Meier GH, 3rd , Panneton JM Subintimal angioplasty: our experience in the treatment of 506 infrainguinal arterial occlusions. J Vasc Surg. 2008;48(4):878-884.

14.

Schmieder GC , Richardson AI , Scott EC , Stokes GK , Meier GH, 3rd , Panneton JM Selective stenting in subintimal angioplasty: analysis of primary stent outcomes. J Vasc Surg. 2008;48(5): 1175-1180; discussion 1180-1171.

15.

Ihnat DM , Duong ST , Taylor ZC , et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score. J Vasc Surg. 2008; 47(5):967-974.

16.

Norgren L. , Hiatt WR , Dormandy JA , et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(supplS):S5-S67.

17.

Verta MJ , Schneider JR , Alonzo M. , Hahn D. Percutaneous Viabahn-assisted subintimal recanalization (VASIR) for severe femoropopliteal occlusive disease. Acta Chir Belg. 2007;107(2): 181-186.

18.

Verta MJ , Schneider JR , Alonzo MJ , Hahn D. Percutaneous Viabahn-assisted subintimal recanalization for severe superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008; 19(4):493-498.

19.

Rutherford RB , Flanigan DP , Gupta SK , et al. Suggested standards for reports dealing with lower extremity ischemia. [erratum appears in J Vasc Surg 1986 Oct;4(4):350]. J Vasc Surg. 1986;4(2):80-94.

20.

Rutherford RB , Baker JD , Ernst C. , et al. Recommended standards for reports dealing with lower extremity ischemia: revised version.[erratum appears in J Vasc Surg 2001 Apr;33(4):805]. J Vasc Surg. 1997;26(3):517-538.

21.

Gray BH , Sullivan TM , Childs MB , Young JR , Olin JW High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty . J Vasc Surg. 1997;25(1):74-83.

22.

Schillinger M. , Sabeti S. , Loewe C. , et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. [see comment]. N Engl J Med. 2006;354(18):1879-1888.

23.

Conte MS Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. J Vasc Surg. 2010; 51(5Suppl):69S-75S.

24.

Duda SH , Bosiers M. , Lammer J. , et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16(3):331-338.

25.

Morice M. -C, Serruys PW , Sousa JE , et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. [see comment]. N Engl J Med. 2002;346(23): 1773-1780.

26.

Adam DJ , Beard JD , Cleveland T. , et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. [see comment]. Lancet. 2005; 366(9501):1925-1934.

27.

Kedora J. , Hohmann S. , Garrett W. , Munschaur C. , Theune B. , Gable D. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease . [see comment]. J Vasc Surg. 2007;45(1):10-16.

28.

Mewissen MW Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vascu Intervent Radiol. 2004;7(1):2-5.

29.

Albiero R. , Adamian M. , Kobayashi N. , et al. Short- and intermediate-term results of (32)P radioactive β-emitting stent implantation in patients with coronary artery disease: the Milan dose-response study.[see comment]. Circulation. 2000;101(1):18-26.

30.

Geraghty PJ Covered stenting of the superficial femoral artery using the Viabahn stent-graft. [see comment]. Perspect Vascu Surg Endovascu Ther. 2006;18(1):39-43.

31.

Fischer M. , Langhoff R. , Schulte K-L. Hemobahn-Endoprosthese: 4-Jahres-Erfahrung mit der perkutanen Anwendung bei Stenosen und Verschlüssen der Arteria femoralis superficialis. [Hemobahn-endoprosthesis: long-term experience (≤4 years follow-up) with percutaneous application in stenoses and occlusions of the superficial femoral artery]. Zentralbl Chir. 2003;128(9):740-745.

32.

Ansel GM , Botti CF Jr , Silver MJ The use of femoropopliteal stent-grafts for critical limb ischemia. Tech Vasc Intervent Radiol. 2005;8(2):140-145.

33.

Alimi YS , Hakam Z. , Hartung O. , et al. Efficacy of Viabahn in the treatment of severe superficial femoral artery lesions: which factors influence long-term patency? [see comment]. Eur J Vasc Endovasc Surg. 2008;35(3):346-352.

34.

Rodriguez-Lopez JA , Soler L. , Werner A. , Martinez E. , Papazoglou K. , Diethrich EB Long-term follow-up of endoluminal grafting for aneurysmal and occlusive disease in the superficial femoral artery. J Endovasc Surg. 1999;6(3):270-277.

35.

Lammer J. , Dake MD , Bleyn J. , et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology. 2000;217(1):95-104.

36.

Bauermeister G. Endovascular stent-grafting in the treatment of superficial femoral artery occlusive disease. J Endovasc Ther Official J Int Soc Endovasc Special. 2001;8(3):315-320.

37.

Bray PJ , Robson WJ , Bray AE Percutaneous treatment of long superficial femoral artery occlusive disease: efficacy of the Hemobahn stent-graft. J Endovasc Ther Official J Int Soc Endovasc Special. 2003;10(3):619-628.

38.

Jahnke T. , Andresen R. , Muller-Hulsbeck S. , et al. Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: midterm results of a prospective trial. J Vasc Interv Radiol. 2003; 14(1):41-51.

39.

Saxon RR , Coffman JM , Gooding JM , Natuzzi E. , Ponec DJ Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol. 2003; 14(3):303-311.

40.

Hartung O. , Otero A. , Dubuc M. , et al. Efficacy of Hemobahn in the treatment of superficial femoral artery lesions in patients with acute or critical ischemia: a comparative study with claudicants. Eur J Vasc Endovasc Surg. 2005;30(3):300-306.

41.

Fischer M. , Schwabe C. , Schulte K-L. Value of the Hemobahn/ Viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. [see comment]. J Endovasc Ther Official J Int Soc Endovasc Special . 2006;13(3):281-290.

42.

Anonymous. Encouraging data for Viabahn in the SFA. Vascular-News. February 2009:8.

43.

Anonymous. Endoluminal peripheral ‘‘bypass’’: a promising alternative. VascularNews. February 2009:8.

44.

Sultan S. , Hynes N. Five-year Irish trial of CLI patients with TASC II type C/D lesions undergoing subintimal angioplasty or bypass surgery based on plaque echolucency . J Endovasc Ther. 2009;16(3):270-283.

45.

Ariyoshi H. , Okuyama M. , Okahara K. , et al. Expanded polytetrafluoroethylene (ePTFE) vascular graft loses its thrombogenicity six months after implantation. Thromb Res. 1997;88(5): 427-433.

46.

Saxon RR , Coffman JM , Gooding JM , Ponec DJ Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions. J Vasc Interv Radiol. 2007; 18(11):1341-1349; quiz 1350.

47.

Dorrucci V. Treatment of superficial femoral artery occlusive disease. J Cardiovasc Surg (Torino). 2004;45(5):193-201.

48.

Lipsitz EC , Ohki T. , Veith FJ , et al. Fate of collateral vessels following subintimal angioplasty . J Endovasc Ther Official J Int Soc Endovasc Special. 2004;11(3):269-273.

49.

Smeets L. , Ho GH , Hagenaars T. , van den Berg JC , Teijink JA , Moll FL Remote endarterectomy: first choice in surgical treatment of long segmental SFA occlusive disease? Eur J Vasc Endovasc Surg. 2003;25:583-589.